Conducta médica versus escala modificada Wood en bronquiolitis aguda

El diagnóstico y clasificación de la severidad de la bronquiolitis se basan en la historia clínica y el examen físico. Actualmente existe una variabilidad en el ámbito clínico en el uso de los predictores de hospitalización de estos pacientes. En Colombia debido al número limitado de camas hospitalarias, es importante diferenciar y clasificar adecuadamente el lugar de manejo para cada paciente, según sus características clínicas, antecedentes y rasgos sociodemográficos. De esta manera se evitará la morbilidad y mortalidad de los pacientes por esta causa, se dará un manejo oportuno y se optimizará un recurso limitado. La escala de severidad clínica de asma modificada de Wood (M-WCAS), combina síntomas y signos encontrados al examen físico para clasificar la severidad de la bronquiolitis aguda. Esta escala fue validada en Colombia en el año 2013 y podría ser un instrumento que apoye la toma de decisiones clínicas de estos pacientes en cuanto al lugar de manejo.

Clinical experience of clobazam as add-on treatment in a cohort of adults with epilepsy

Objective: Epilepsy is a common neurologic disorder affecting 1% of the world population with one-third of these patients failing to have seizure control for more than one year. Clobazam is a long-acting benzodiazepine used worldwide for the treatment of epilepsy. This antiepileptic drug has demonstrated great clinical benefits with mild side effects. The objective of this study was to better understand the efficacy of clobazam treatment on adult patients with refractory epilepsy. Design: A retrospective review of 44 adult patients with diagnosis of epilepsy that were seen at our Epilepsy Clinic between January 2014 and May 2015. Setting: An outpatient epilepsy clinic at the Hospital Universitario Fundación Santa Fe de Bogota, Colombia. Participants: 44 adult patients with diagnosis of epilepsy. Measurements: Seizure frequency, adverse effects and the use of concomitant AEDs were reviewed in each of the patient´s clinical charts. Results: The responder rate of patients with clobazam was 52% at 3 months, 50% at 6 months and 55% at 12 month. Seizure freedom rates at 3, 6 and 12 months were 18%, 25% and 25% respectively. Clobazam related adverse events occurred only in four patients (9%) at the end of the twelve months with somnolence being the most common. Conclusion: These findings suggest that clobazam treatment in adult patients with focal or generalized epilepsy is effective and safe. Its use should be considered early when first-line agents fail to provide seizure control.